![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WR Martin, CG Eades, JA Thompson, RE Huppler and PE Gilbert
Three different syndromes produced by congeners of morphine have been identified in the nondependent chronic spinal dog. These syndromes have been attributed to interaction of agonists with three distinguishable receptors (mu, kappa and sigma). Morphine is the prototype agonist for the mu receptor, ketocyclazocine for the kappa receptor and SKF-10,047 for the sigma receptor. The morphine syndrome (mu) in the dog is characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifference to environmental stimuli. Ketocyclazocine (kappa) constricts pupils, depresses the flexor reflex and produces sedation but does not markedly alter pulse rate or the skin twitch reflex. SKF-10,047 (sigma), in contrast to morphine and ketocyclazocine, causes mydriasis, tachypnea, tachycardia and mania. The effects of these three drugs can be antagonized by the pure antagonist naltrexone, indicating that they are agonists. Further, chronic administration of morphine, ketocyclazocine and SKF-10,047 induces tolerance to their agonistic effects. Morphine suppresses abstinence in morphine-dependent dogs while ketocyclazocine does not. Ketocyclazocine at best precipitated only a liminal abstinence syndrome in the morphine-dependent dog, indicating that it had little affinity for the morphine receptor. Ketocyclazocine thus appears to be a selective agonist at the kappa receptor. Further, it has been shown that buprenorphine is a partial agonist of the mu type which both suppressed and precipitated abstinence in the morphine-dependent dog while morphine and propoxyphene are stronger agonists. Apomorphine and SKF-10,047 produce similar pharmacologic effects suggesting that sigma activity may involve a dopaminergic mechanism.
This article has been cited by other articles:
|
|
 |
|
  S. Dreborg, G. Sundstrom, T. A. Larsson, and D. Larhammar Evolution of vertebrate opioid receptors PNAS, October 7, 2008; 105(40): 15487 - 15492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pal, U. B. Chu, S. Ramachandran, D. Grawoig, L.-W. Guo, A. R. Hajipour, and A. E. Ruoho Juxtaposition of the Steroid Binding Domain-like I and II Regions Constitutes a Ligand Binding Site in the {sigma}-1 Receptor J. Biol. Chem., July 11, 2008; 283(28): 19646 - 19656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Palmer, R. Mahen, E. Schnell, M. B.A. Djamgoz, and E. Aydar Sigma-1 Receptors Bind Cholesterol and Remodel Lipid Rafts in Breast Cancer Cell Lines Cancer Res., December 1, 2007; 67(23): 11166 - 11175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pal, A. R. Hajipour, D. Fontanilla, S. Ramachandran, U. B. Chu, T. Mavlyutov, and A. E. Ruoho Identification of Regions of the {sigma}-1 Receptor Ligand Binding Site Using a Novel Photoprobe Mol. Pharmacol., October 1, 2007; 72(4): 921 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mei and G. W. Pasternak Modulation of Brainstem Opiate Analgesia in the Rat by {sigma}1 Receptors: A Microinjection Study J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1278 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Martin, R. A. Hurley, and K. H. Taber Is Opiate Addiction Associated With Longstanding Neurobiological Changes? J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 242 - 248. [Full Text] [PDF]
|
|
|
|
|
|
C. Zeng, S. Vangveravong, J. Xu, K. C. Chang, R. S. Hotchkiss, K. T. Wheeler, D. Shen, Z.-P. Zhuang, H. F. Kung, and R. H. Mach Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy Cancer Res., July 15, 2007; 67(14): 6708 - 6716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Monassier, B. Manoury, C. Bellocq, J. Weissenburger, H. Greney, D. Zimmermann, J.-D. Ehrhardt, P. Jaillon, I. Baro, and P. Bousquet {sigma}2-Receptor Ligand-Mediated Inhibition of Inwardly Rectifying K+ Channels in the Heart J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 598 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Renaudo, S. L'Hoste, H. Guizouarn, F. Borgese, and O. Soriani Cancer Cell Cycle Modulated by a Functional Coupling between Sigma-1 Receptors and Cl- Channels J. Biol. Chem., January 26, 2007; 282(4): 2259 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Bermack and G. Debonnel Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors J Psychopharmacol, January 1, 2007; 21(1): 85 - 92. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Martina, M.-E. B. Turcotte, S. Halman, and R. Bergeron The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus J. Physiol., January 1, 2007; 578(1): 143 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ansonoff, J. Zhang, T. Czyzyk, R. B. Rothman, J. Stewart, H. Xu, J. Zjwiony, D. J. Siebert, F. Yang, B. L. Roth, et al. Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of {kappa}-Opioid Receptor-1 Knockout Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 641 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Azzariti, N. A. Colabufo, F. Berardi, L. Porcelli, M. Niso, G. M. Simone, R. Perrone, and A. Paradiso Cyclohexylpiperazine derivative PB28, a {sigma}2 agonist and {sigma}1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther., July 1, 2006; 5(7): 1807 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rowland, Z. Tu, J. Xu, D. Ponde, R. H. Mach, and M. J. Welch Synthesis and In Vivo Evaluation of 2 High-Affinity 76Br-Labeled {sigma}2-Receptor Ligands J. Nucl. Med., June 1, 2006; 47(6): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Baker, A. M Best, P. A Pade, and E. F McCance-Katz Effect of Buprenorphine and Antiretroviral Agents on the QT Interval in Opioid-Dependent Patients Ann. Pharmacother., March 1, 2006; 40(3): 392 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Uchida, H. Ujike, Y. Tanaka, A. Sakai, M. Yamamoto, Y. Fujisawa, A. Kanzaki, and S. Kuroda A Variant of the Sigma Receptor Type-1 Gene Is a Protective Factor for Alzheimer Disease Am J Geriatr Psychiatry, December 1, 2005; 13(12): 1062 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-X. Pan, J. Xu, E. Bolan, H. S. Moskowitz, M. Xu, and G. W. Pasternak Identification of Four Novel Exon 5 Splice Variants of the Mouse {micro}-Opioid Receptor Gene: Functional Consequences of C-Terminal Splicing Mol. Pharmacol., September 1, 2005; 68(3): 866 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Vocci, J. Acri, and A. Elkashef Medication Development for Addictive Disorders: The State of the Science Am J Psychiatry, August 1, 2005; 162(8): 1432 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stevenson, J. E. Folk, K. C. Rice, and S. S. Negus Interactions between {delta} and {micro} Opioid Agonists in Assays of Schedule-Controlled Responding, Thermal Nociception, Drug Self-Administration, and Drug versus Food Choice in Rhesus Monkeys: Studies with SNC80 [(+)-4-[({alpha}R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Heroin J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 221 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yassen, E. Olofsen, A. Dahan, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1136 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Likar and R. Sittl Transdermal Buprenorphine for Treating Nociceptive and Neuropathic Pain: Four Case Studies Anesth. Analg., March 1, 2005; 100(3): 781 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aydar, C. P. Palmer, and M. B. A. Djamgoz Sigma Receptors and Cancer: Possible Involvement of Ion Channels Cancer Res., August 1, 2004; 64(15): 5029 - 5035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bermack, N. Haddjeri, and G. Debonnel Effects of the Potential Antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone Monomethanesulfonate] a Combined {sigma} and 5-HT1A Ligand: Modulation of Neuronal Activity in the Dorsal Raphe Nucleus J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 578 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Vanderah, C. D. Schteingart, J. Trojnar, J.-L. Junien, J. Lai, and P. J.-M. Riviere FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A Peripheral Efficacious {kappa} Opioid Agonist with Unprecedented Selectivity J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stevenson, J. E. Folk, D. C. Linsenmayer, K. C. Rice, and S. S. Negus Opioid Interactions in Rhesus Monkeys: Effects of {delta} + {micro} and {delta} + {kappa} Agonists on Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1054 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lutfy, S. Eitan, C. D. Bryant, Y. C. Yang, N. Saliminejad, W. Walwyn, B. L. Kieffer, H. Takeshima, F. I. Carroll, N. T. Maidment, et al. Buprenorphine-Induced Antinociception Is Mediated by {micro}-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors J. Neurosci., November 12, 2003; 23(32): 10331 - 10337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Mtchedlishvili and J. Kapur A Presynaptic Action of the Neurosteroid Pregnenolone Sulfate on GABAergic Synaptic Transmission Mol. Pharmacol., October 1, 2003; 64(4): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Fudala, T. P. Bridge, S. Herbert, W. O. Williford, C. N. Chiang, K. Jones, J. Collins, D. Raisch, P. Casadonte, R. J. Goldsmith, et al. Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone N. Engl. J. Med., September 4, 2003; 349(10): 949 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nuwayhid and L. L. Werling Steroids Modulate N-Methyl-D-aspartate-Stimulated [3H]Dopamine Release from Rat Striatum via {sigma} Receptors J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 934 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi and T.-P. Su {sigma}-1 Receptors ({sigma}1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 718 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mizoguchi, A. Spaulding, R. Leitermann, H.-E. Wu, H. Nagase, and L. F. Tseng Buprenorphine Blocks {epsilon}- and {micro}-Opioid Receptor-Mediated Antinociception in the Mouse J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 394 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Morinville, C. M. Cahill, M. J. Esdaile, H. Aibak, B. Collier, B. L. Kieffer, and A. Beaudet Regulation of {delta}-Opioid Receptor Trafficking via {micro}-Opioid Receptor Stimulation: Evidence from {micro}-Opioid Receptor Knock-Out Mice J. Neurosci., June 15, 2003; 23(12): 4888 - 4898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takebayashi, T. Hayashi, and T.-P. Su Nerve Growth Factor-Induced Neurite Sprouting in PC12 Cells Involves sigma -1 Receptors: Implications for Antidepressants J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1227 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Bolan, R. J. Tallarida, and G. W. Pasternak Synergy between {micro} Opioid Ligands: Evidence for Functional Interactions among {micro} Opioid Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Roth, K. Baner, R. Westkaemper, D. Siebert, K. C. Rice, S. Steinberg, P. Ernsberger, and R. B. Rothman Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist PNAS, September 3, 2002; 99(18): 11934 - 11939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. McKay and L. K. Kaczmarek Act Locally: New Ways of Regulating Voltage-Gated Ion Channels Mol. Interv., July 1, 2002; 2(4): 215 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Derbez, R. M. Mody, and L. L. Werling sigma 2-Receptor Regulation of Dopamine Transporter via Activation of Protein Kinase C J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Newman, S. S. Sands, D. R. Wallace, and C. W. Stevens Characterization of {micro}, kappa , and delta Opioid Binding in Amphibian Whole Brain Tissue Homogenates J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 364 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mei and G. W. Pasternak sigma 1 Receptor Modulation of Opioid Analgesia in the Mouse J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1070 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Platt, J. K. Rowlett, and R. D. Spealman Discriminative Stimulus Effects of Intravenous Heroin and Its Metabolites in Rhesus Monkeys: Opioid and Dopaminergic Mechanisms J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi and T.-P. Su Regulating ankyrin dynamics: Roles of sigma-1 receptors PNAS, January 5, 2001; (2001) 21413698. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. T. Williams, M. J. Christie, and O. Manzoni Cellular and Synaptic Adaptations Mediating Opioid Dependence Physiol Rev, January 1, 2001; 81(1): 299 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi, T. Maurice, and T.-P. Su Ca2+ Signaling via sigma 1-Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca2+ Concentration J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 788 - 798. [Abstract] [Full Text]
|
|
|
|
 |
|
 J L Turvill, P Kasapidis, and M J G Farthing The sigma ligand, igmesine, inhibits cholera toxin and Escherichia coli enterotoxin induced jejunal secretion in the rat Gut, October 1, 1999; 45(4): 564 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Platt, D. M. Grech, J. K. Rowlett, and R. D. Spealman Discriminative Stimulus Effects of Morphine in Squirrel Monkeys: Stimulants, Opioids, and Stimulant-Opioid Combinations J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1092 - 1100. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Brandt, S. S. Negus, N. K. Mello, M. S. Furness, X. Zhang, and K. C. Rice Discriminative Stimulus Effects of the Nonpeptidic delta -Opioid Agonist SNC80 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1157 - 1164. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Soriani, F. le Foll, L. Galas, F. Roman, H. Vaudry, and L. Cazin The sigma -ligand (+)-pentazocine depresses M current and enhances calcium conductances in frog melanotrophs Am J Physiol Endocrinol Metab, July 1, 1999; 277(1): E73 - E80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Wilke, R. P. Mehta, P. J. Lupardus, Y. Chen, A. E. Ruoho, and M. B. Jackson Sigma Receptor Photolabeling and Sigma Receptor-mediated Modulation of Potassium Channels in Tumor Cells J. Biol. Chem., June 25, 1999; 274(26): 18387 - 18392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Law and H. H. Loh Regulation of Opioid Receptor Activities J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 607 - 624. [Abstract] [Full Text]
|
|
|
|
|
|
O. Soriani, F. L. Foll, F. Roman, F. P. Monnet, H. Vaudry, and L. Cazin A-Current Down-Modulated by sigma Receptor in Frog Pituitary Melanotrope Cells Through a G Protein-Dependent Pathway J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 321 - 328. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Osinski, P. Bass, and E. A. Gaumnitz Peripheral and central actions of orphanin FQ (nociceptin) on murine colon Am J Physiol Gastrointest Liver Physiol, January 1, 1999; 276(1): G125 - G131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Soriani, H. Vaudry, Y. A. Mei, F. Roman, and L. Cazin Sigma Ligands Stimulate the Electrical Activity of Frog Pituitary Melanotrope Cells through a G-Protein-Dependent Inhibition of Potassium Conductances J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 163 - 171. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus, M. B. Gatch, N. K. Mello, X. Zhang, and K. Rice Behavioral Effects of the Delta-Selective Opioid Agonist SNC80 and Related Compounds in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 362 - 375. [Abstract] [Full Text]
|
|
|
|
|
|
T. E. Schlaepfer, E. C. Strain, B. D. Greenberg, K. L. Preston, E. Lancaster, G. E. Bigelow, P. E. Barta, and G. D. Pearlson Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects Am J Psychiatry, April 1, 1998; 155(4): 470 - 473. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Zhu, M.-S. Hsu, and J. E. Pintar Developmental Expression of the µ, kappa , and delta Opioid Receptor mRNAs in Mouse J. Neurosci., April 1, 1998; 18(7): 2538 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
